Blood Cancer United Inc 2020 AR2
The report highlights the progress made by The Leukemia & Lymphoma Society (LLS) during the fiscal year 2020 despite the challenges of the COVID-19 pandemic. LLS supported over 190 active research grants and 20 Therapy Acceleration Program partnerships, dedicating $186 million in multi-year funding. The organization provided $142 million in financial assistance to patients, including launching a COVID-19 Patient Financial Aid Program that supported over 19,300 patients. LLS also advanced advocacy efforts, securing Medicare payment increases for CAR-T treatments and a federal ban on surprise medical bills. Additionally, LLS launched its Children's Initiative to advance pediatric cancer research and reinforced its commitment to diversity, equity, and inclusion.
Company: Blood Cancer United Inc
Sector: Healthcare & social services
Country: United States
Year: 2020
Type: AR2
Pages: 20
Back to company
Blood Cancer United Inc
Annual Report
The report highlights the progress made by The Leukemia & Lymphoma Society (LLS) during the fiscal year 2020 despite the challenges of the COVID-19 pandemic. LLS supported over 190 active research grants and 20 Therapy Acceleration Program partnerships, dedicating $186 million in multi-year funding. The organization provided $142 million in financial assistance to patients, including launching a COVID-19 Patient Financial Aid Program that supported over 19,300 patients. LLS also advanced advocacy efforts, securing Medicare payment increases for CAR-T treatments and a federal ban on surprise medical bills. Additionally, LLS launched its Children's Initiative to advance pediatric cancer research and reinforced its commitment to diversity, equity, and inclusion.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jul 1, 2019 - Jun 30, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
No data available